Medicare Considers Coverage Policy For Genetic Warfarin Dosing Tests

CMS opened a national coverage analysis Aug. 4 to collect data on whether pharmacogenetic testing to determine sensitivity to the anti-clotting drug warfarin really improves overall health outcomes